Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products.
$63.43+1.78%
报价 2026-11-13
市值
$129.66B
EV
$153.01B
PE (TTM)
16.5x
预期 PE (FY2026)
9.8x
52 周区间距高点 -6.8%
$45.79$68.09
筛选结果
pipeline · 2026-11-13Filter✗ 高增长✗ Cheap✗ GARP
does not hit growth, cheap, or GARP pool
爆发潜力
2026-11-13未命中✗ 收入线✗ EPS 线
| 财年 | 收入倍数 | EPS | PE |
|---|---|---|---|
| FY+22027-12 | 1.0x | 6.23 → 6.70（1.1x） | 9.5 |
| FY+32028-12 | 0.8x | 6.23 → 5.30（0.9x） | 12.0 |
毛利率 68% · TTM 收入 $50034M · 基数 EPS 6.23（调整后）
电话会信号
辅助标签Q3 20262026-10-29
扩产AI 词频高上调指引
指引 上调
信心 4
分析师 4
“We are well positioned to deliver long term durable growth into the next decade, driven by a diversified growth portfolio and pipeline.”
原文引用（2）
- 扩产：approximately $2.3 billion investment that will create nearly 500 skilled jobs
- 上调指引：Based on the strength of our results, we are raising our full year guidance
蓝色标签在暴涨研究中略有区分度；悬停查看口径。
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| BMYBristol-Myers Squibb Company PFD CONV 2 | $129.66B | +1.8% | +4.6% | 67.7% | 16.5x | 10.5x | 14.0x | |
| PFEPfizer Inc. | $164.67B | +0.2% | +1.7% | 72.8% | 37.3x | 17.7x | 14.7x | |
| VRTXVertex Pharmaceuticals Incorporated | $136.56B | -0.7% | +10.6% | 86.3% | 29.0x | 23.5x | 42.6x | |
| MCKMcKesson Corporation | $127.33B | +2.4% | +6.5% | 3.6% | 24.9x | 17.6x | 18.4x | |
| SNYSanofi | $115.9B | -0.2% | – | 71.7% | 8.9x | 9.7x | – | |
| CVSCVS Health Corporation | $114.32B | -0.5% | +5.2% | 13.8% | 51.2x | 17.8x | 7.3x | |
| HCAHCA Healthcare, Inc. | $104.25B | -0.3% | +4.5% | 14.9% | 16.7x | 9.9x | 17.7x | |
| GSKGSK plc | $101.13B | +0.5% | – | 72.5% | 13.7x | 7.8x | – | |
| ELVElevance Health Inc. | $92.84B | -0.0% | +0.7% | 25.6% | 11.3x | 9.1x | 14.3x | |
| 同行中位数 | – | – | +4.8% | 48.7% | 20.8x | 13.8x | 16.2x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。